NASDAQ · Biotechnology

Oric Pharmaceuticals, Inc. (ORIC) Stock

$11.99 -0.33% NASDAQ: ORIC Healthcare

Valuation

MetricValue
Price$11.99
Market Cap$1.24B
P/E Ratio-9.25
P/B Ratio3.54
P/S Ratio0.00
EPS (TTM)$-1.54
52-Week High$14.93
52-Week Low$7.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.35%
ROA-34.68%
ROCE-40.67%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio14.40

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-79.0M$-92.0M$-111.0M$-143.0M$-143.0M
Net Profit$-79.0M$-89.0M$-101.0M$-128.0M$-129.0M
EPS$-2.07$-2.25$-1.96$-1.83$-1.47
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$299.0M$250.0M$255.0M$274.0M$411.0M
Total Liabilities$26.0M$28.0M$31.0M$31.0M$27.0M
Cash$226.0M$67.0M$23.0M$59.0M$46.0M
Borrowings$2.0M$12.0M$10.0M$3.0M$12.0M

Latest News

ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer MT Newswires · Jul 14, 2026 ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer GlobeNewswire · Jul 14, 2026 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire · May 27, 2026 Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth Simply Wall St. · May 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-60.0M$-75.0M$-86.0M$-113.0M$-113.0M
Investing Cash Flow$157.0M$-111.0M$-44.0M$21.0M$-149.0M
Financing Cash Flow$-1.0M$0$1.0M$2.0M$0
Net Cash Flow$148.0M$-159.0M$-43.0M$36.0M$-14.0M
Free Cash Flow$-60.0M$-77.0M$-87.0M$-114.0M$-114.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.26
EV / EBITDA-8.80
FCF Yield-8.69%
Quick Ratio13.19
Interest Coverage0.00
Return 1Y-7.71%
Return 3Y23.47%
Return 5Y-45.48%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc. is led by CEO Jacob Chacko, employs 122 people, headquartered in US, publicly traded since 2020.

Oric Pharmaceuticals, Inc. (ORIC) stock trades at $11.99 with a market capitalization of $1.24B. The stock is valued at a price-to-earnings (P/E) ratio of -9.25, price-to-book of 3.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.23 and $14.93, and currently trades 19.7% below its 52-week high.

On profitability, Oric Pharmaceuticals, Inc. generates a return on equity (ROE) of -35.35%, return on capital employed of -40.67%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides